Robert Breedlove
Fortune : 493 896 $ au 30/09/2026
Fortune : 493 896 $ au 30/09/2026
Robert Breedlove is Chief Accounting Officer & Vice President-Finance at Phathom Pharmaceuticals, Inc. since 2025.
Former roles include Manager-Financial Reporting & Compliance at NeoGenomics, Inc. and Senior Manager at Van Den Boom & Associates LLC.
Education includes an undergraduate degree from the University of San Diego.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 03/09/2026 | 67 657 ( 0,08 % ) | 493 896 $ | 30/09/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 06/10/2025 |
| Sociétés | Poste | Fin |
|---|---|---|
| NEOGENOMICS, INC. | Compliance Officer | - |
Van Den Boom & Associates LLC
Van Den Boom & Associates LLC Miscellaneous Commercial ServicesCommercial Services Provides accounting, financial, payroll, benefit and human resource services | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
NeoGenomics, Inc.
NeoGenomics, Inc. Medical/Nursing ServicesHealth Services Provides genetic and molecular testing services | Health Services |
University of San Diego
University of San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Van Den Boom & Associates LLC
Van Den Boom & Associates LLC Miscellaneous Commercial ServicesCommercial Services Provides accounting, financial, payroll, benefit and human resource services | Commercial Services |
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel treatments for gastrointestinal diseases and disorders | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national